Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates
Provided By GlobeNewswire
Last update: May 13, 2025
Company had a strong start to 2025, emerging as an R&D-focused organization
Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025
Read more at globenewswire.comNASDAQ:LXRX (7/31/2025, 2:26:44 PM)
1.095
+0.07 (+7.35%)
Find more stocks in the Stock Screener
